Companies · Biotechnology

Duke Street Bio Ltd

LONDON · Biotechnology

Diligence memoA one-page analyst read on Duke Street Bio Ltd — recommendation, valuation, rhythm, risks.
$5.1M
Total raised · real
3
Rounds
1.0×
Latest step-up
Top 56%
Sector rank · raised
Seed
Latest stage · inferred · Wed Jan 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Duke Street Bio Ltd looks fair against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.13× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.
  • Within the normal band (113% of peer median) for its niche.
At-risk
  • Last raise 2.5 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Duke Street Bio Ltd is one of 4291 Biotechnology companies tracked from LONDON. By capital raised it ranks mid-pack (ahead of 45% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2020
Year incorporated
2024-01-03
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2021-05-24 Raised $142K (real) Modeled valuation $4.5M (est)$142K$4.5MPre-Seed2021Seed · 2022-05-16 Raised $2.4M (real) Modeled valuation $38M (est)$2.4M$38MSeed2022Seed · 2024-01-03 Raised $2.5M (real) Modeled valuation $16M (est)$2.5M$16MSeed2024+$2.4M+$2.5MCumulative $5.1M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$142K · 2021
Seed$2.4M · 2022
Seed extension$2.5M · 2024

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$16.1M
Base estimate est.
$1.8M
Conservative case
$48.9M
Upside case
$12.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $4.5M · 2021-05-242021Seed · modeled $38.4M · 2022-05-16Seed · modeled $16.1M · 2024-01-032024
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
2.5 yr
Elapsed time used
2.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
16 mo
Avg between rounds
$2.0M/yr
Capital velocity
5.1 yr
On record since
2021
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.7× of median
This company$5.1M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.5× above median
This company$2.5M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$16.1M
Sector median$64.2M

Raised more than 45% of sector peers (real $). Modeled value above 25% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #92 of 207.

This companyCohort peer
$10.0M$100.0M$1.0M$10.0MCapital raised (log)Mesentech Inc. · Seed Raised $3.9M · modeled $65.6M (est)Marlinspike Therapeutics, Inc. · Seed Raised $3.5M · modeled $64.3M (est)Microbial Machines, Inc. · Seed Raised $3.9M · modeled $63.6M (est)Pearl Diagnostics, Inc. · Seed Raised $3.5M · modeled $62.8M (est)Crossfire Medical Inc · Seed Raised $3.0M · modeled $57.5M (est)Design Pharmaceuticals, Inc. · Seed Raised $3.0M · modeled $56.9M (est)Tekv Holdings LLC · Seed Raised $4.0M · modeled $55.4M (est)Mi-Helper, Inc. · Seed Raised $4.0M · modeled $50.9M (est)Thelium Therapeutics Inc. · Seed Raised $3.1M · modeled $50.7M (est)Turtle Health, Inc. · Seed Raised $2.7M · modeled $49.1M (est)Accufix Holdings, Inc. · Seed Raised $4.2M · modeled $46.7M (est)Kyttaro Ltd · Seed Raised $5.2M · modeled $45.5M (est)Duke Street Bio Ltd (this company) Raised $5.1M · modeled $16.1M (est)Duke Street Bio Ltd
CompanyStageRaised · realValue · estvs peer med.
Mesentech Inc.Seed$3.9M$65.6M4.61×
Marlinspike Therapeutics, Inc.Seed$3.5M$64.3M4.52×
Microbial Machines, Inc.Seed$3.9M$63.6M4.47×
Pearl Diagnostics, Inc.Seed$3.5M$62.8M4.41×
Crossfire Medical IncSeed$3.0M$57.5M4.04×
Design Pharmaceuticals, Inc.Seed$3.0M$56.9M4.00×
Tekv Holdings LLCSeed$4.0M$55.4M3.89×
Mi-Helper, Inc.Seed$4.0M$50.9M3.58×
Thelium Therapeutics Inc.Seed$3.1M$50.7M3.56×
Turtle Health, Inc.Seed$2.7M$49.1M3.45×
Accufix Holdings, Inc.Seed$4.2M$46.7M3.28×
Kyttaro LtdSeed$5.2M$45.5M3.20×
Duke Street Bio Ltd this companySeed$5.1M$16.1M1.13×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$142K2021-05-24$787K$4.5M90%
Seed$2.4M2022-05-16$12.2M$38.4M90%
Seed$2.5M2024-01-03$12.6M$16.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$142K2021-05-24
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Seed$2.4M2022-05-16
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 17.2× larger than the prior — scaling up.
    • 1 investor on this round.
  3. Seed$2.5M2024-01-03
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
Intelligence
2025 ~Q2
Modeled next raise · ~16mo cadence
$2.6M
Modeled next size est.range $2.5M$4.2M
1.0×
Last step-up
$2.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Alan Wise2021-05
Donnie Christian2021-05
Harvey McGrath2022-05
Peter Trill2021-05
Phillip Cowley2021-05
Registry & provenance

Duke Street Bio Ltd is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1823388
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Oncoscope IncBiotechnologySeed$5.2M$20.0Msame sector · same stage
Intellicell Biosciences, Inc.BiotechnologySeed$5.4M$16.7Msame sector · same stage
Ampel, LLCBiotechnologySeed$4.8M$16.7Msame sector · same stage
SymbioCellTech, LLCBiotechnologySeed$4.8M$12.7Msame sector · same stage
Contamination Source Identification LLCBiotechnologySeed$4.7M$15.7Msame sector · same stage
Sinapis Pharma, Inc.BiotechnologySeed$4.6M$15.0Msame sector · same stage
InnAVasc Medical, Inc.BiotechnologySeed$4.6M$21.1Msame sector · same stage
RCE Technologies, Inc.BiotechnologySeed$5.8M$14.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Carolina Molecular Inc.BiotechnologySeed$2.8M86%
Summit Street Medical LLCBiotechnologySeed$82.6M84%
Carcinotech Ltd.BiotechnologyPre-Seed$3.2M84%
Bio-Path Holdings IncBiotechnologySeed$16.6M84%
Basking Biosciences, Inc.BiotechnologySeries B$261.0M84%
Rowan Scientific CorpBiotechnologySeed$11.0M84%
Vitanova Biomedical, Inc.BiotechnologyPre-Seed$17.9M84%
CytoBioscience, Inc.BiotechnologySeries B$60.7M84%
Frequently asked
How much funding has Duke Street Bio Ltd raised?
Duke Street Bio Ltd has raised approximately $5.1M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Duke Street Bio Ltd's estimated valuation?
Provath's modeled valuation for Duke Street Bio Ltd is approximately $16.1M (modeled range $1.8M–$48.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Duke Street Bio Ltd at?
Duke Street Bio Ltd's latest modeled financing stage is Seed. Its most recent recorded round closed around Wed Jan 03.
What does Duke Street Bio Ltd do and where is it based?
Duke Street Bio Ltd operates in the Biotechnology sector, based in LONDON.
Explore related

See where Duke Street Bio Ltd sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Duke Street Bio Ltd, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.